VolitionRX announces funding for veterinary project

We helped our client VolitionRX to announce the confirmation of a further $500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its subsidiary Volition Veterinary Diagnostics Development, LLC.

Video footage was fed from the signing ceremony in the USA and we then edited the ‘rushes’ with existing Volition material to produce a video to accompany the press announcement of the deal.

To see Volition’s video page, click here

Volition announced the signing of multiple agreements to collaborate with Texas A&M University (“Texas A&M”), a leading U.S. institution to develop Nu.QTMVet products.

“We are delighted with the non-dilutive financial support we continue to receive as it allows us to develop Nu.QTMVet products in the very exciting veterinary market. We would like to thank SOFINEX for this latest loan which takes our non-dilutive funding total from local agencies and the Walloon government to over $6 million to-date,” commented Dr. Gaetan Michel, Chief Executive Officer of Belgian Volition.

 The signing ceremony took place at the Texas A&M campus, hosted by Dean Eleanor M. Green, DVM, DACVIM, DABVP. Also in attendance were: Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department; Chantal De Bleu, Director General and Phillipe La Chappelle, Director of Innovation of AWEX, the Wallonia Export-Investment Agency; members of the Volition Executive team including Chairman, Dr. Martin Faulkes and Chief Executive Officer, Cameron Reynolds.

“It was important to form a U.S. based Volition Veterinary subsidiary to enable dedicated focus on the development and commercialization of our Nu.QTM Vet products and help drive product development and early revenue for the company,” commented Cameron Reynolds, President and Chief Executive Officer of Volition. “I am delighted to welcome Nathan, a highly experienced business development executive and Texas A&M University alumni to our expanding Volition team.”

Mr. Dewsbury has global expertise in the animal health industry having direct involvement in national testing programs, current health diagnostics platforms and commercializing next generation diagnostics. He has a strong background in forming new commercial teams as well as launching and growing successful animal focused startups, all to achieve a global impact on the lives of animals. Mr. Dewsbury was educated at Texas A&M University where he received both his science and business degrees.